Related Experiment Videos
Plasma mevalonate concentrations in uremic patients
A Scoppola1, P De Paolis, G Menzinger
1Cattedra di Endocrinologia Università di Roma Tor Vergata, Italy.
Kidney International
|March 1, 1997
Summary
Patients with chronic renal failure have elevated mevalonic acid (MVA) levels, a cholesterol precursor, which correlate with kidney dysfunction. Hemodialysis significantly reduces MVA, but levels rebound within 24 hours.
Area of Science:
- Biochemistry
- Nephrology
- Metabolic Disorders
Background:
- Mevalonic acid (MVA) is a critical precursor in cholesterol biosynthesis.
- Kidney function influences MVA metabolism and plasma concentrations.
- Elevated MVA may indicate increased endogenous cholesterol synthesis.
Purpose of the Study:
- To assess plasma MVA levels in patients with chronic renal failure (CRF).
- To investigate the relationship between MVA and creatinine levels in CRF.
- To evaluate the impact of hemodialysis on plasma MVA in end-stage renal disease (ESRD).
Main Methods:
- Measured plasma MVA concentrations in CRF patients and controls.
- Correlated MVA levels with plasma creatinine in CRF patients.
- Assessed MVA changes before and after a single hemodialysis session in ESRD patients.
Main Results:
- CRF patients showed significantly higher basal MVA levels than controls (13.3 vs. 4.68 ng/ml).
- A strong positive correlation was found between plasma MVA and creatinine in CRF patients (r=0.86).
- Hemodialysis reduced plasma MVA by 57% four hours post-treatment, with levels returning to baseline within 24 hours.
Conclusions:
- Decreased renal function is associated with elevated plasma MVA concentrations.
- Plasma MVA levels directly correlate with the severity of kidney failure.
- Hemodialysis effectively, albeit temporarily, lowers elevated MVA levels in ESRD patients.